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IGCR1 IS A NOVEL CELL-SURFACE MOLECULE 
VICTORIA MOORE 
ABSTRACT 
 Tumor angiogenesis, the ability of tumor cells to stimulate blood vessel growth, is 
one the most critical steps of tumor progression. To support the growth of the expanding 
tumor, the “angiogenic switch” is turned on, which is often triggered by hypoxia (i.e., 
low oxygen)-mediated events such as expression of vascular endothelial growth factor 
(VEGF), causing normally quiescent endothelial cells to proliferate and sprout.  
An emerging picture of angiogenesis suggests that while governed by complex 
mechanisms, cell adhesion molecules (CAMs) plays a pivotal role in the regulation of 
angiogenesis. Our laboratory recently identified multiple previously unknown proteins 
including, transmembrane and immunoglobulin domain containing 1 (TMIGD1) and 
immunoglobulin-containing and proline-rich receptor 1 (IGPR1). Immunoglobulin-
containing and cysteine-rich receptor 1 (IGCR1) represents the third remember of IGPR-
1 family proteins. To investigate the expression and function of IGCR1, we have 
developed a rabbit polyclonal anti-IGCR1 antibody and demonstrated that IGCR1 is 
expressed in the endothelial cells of human blood vessels. To examine possible function 
of IGCR1, we have generated porcine aortic endothelial (PAE) cells over-expressing 
IGCR1. We demonstrate that IGCR1 expression in PAE cells inhibited cell proliferation 
and capillary tube formation as measured by colorimetric MTT and matrigel tube 
formation assays, respectively. In contrast, over-expression of IGCR1 in PAE cells 
inhibited cell migration as measured by wounding assay. Taken together, this study 
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identifies IGCR1 as a novel regulator of angiogenesis. Given, angiogenesis is a highly 
coordinated cellular processes controlled spatially and temporally by a myriad of cell 
surface receptors and ligands, IGCR1 by modulating the rate of endothelial cell 
proliferation and migration, plays a significant role in the formation of blood vessels.      
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INTRODUCTION 	  
Angiogenesis is the biological process of blood vessel formation from existing 
blood vessels. Angiogenesis can occur in one of two manners -described as sprouting and 
nonsprouting- each of which produce distinct blood vessel morphologies. Sprouting 
angiogenesis is a more common approach and results in new vessels branching out from 
the existing vessel, while nonsprouting, also called intussuception, occurs less frequently 
and results in one vessel splitting itself into two, which allows for new capillary 
formation while maintaining the same number of endothelial cells (Conway et. al, 2001). 
Angiogenesis is vital in embryonic development and plays a critical in normal 
physiological processes such as wound healing, the menstrual cycle and hair growth. 
Moreover, aberrant angiogenesis is a key hallmark of many human diseases ranging from 
cancer to inflammation and age-related macular degeneration (Folkman, 2006).  
Regardless of the type of vessel formation, during angiogenesis, endothelial cells 
start to proliferate, migrate and form capillary tubes in response to vascular endothelial 
growth factor (VEGF), processes which require an enormous level of coordination among 
signaling factors, adjacent cellular junctions, the basement membrane and the 
extracellular matrix (Chung et. al, 2010). Vasculogenesis, the process of de novo blood 
vessel formation, which occurs during embryonic development, has its own distinct 
process, but of interest, vasculogenic tissue remains circulating even after birth and is 
possibly recruited for vessel growth (Asahara et. al, 1999; Kalka et. al, 2000). While 
major progress is being made to understand the signaling pathways that govern 
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angiogenesis, much of the cellular and molecular interactions that play into this process 
still have yet to be fully understood. 
 
Role of VEGF and VEGF receptors in angiogenesis 
Vascular endothelial growth factors (VEGFs) and their corresponding receptor 
(VEGFR) family compose a large group of ligand-receptors, whose interactions have 
been demonstrated to be required for numerous essential vascular processes, which 
include hematopoietic/endothelial cell differentiation (Shalaby et. al, 1995), 
endothelial/vascular smooth muscle cell differentiation (Yamashita et. al, 2000) and 
vasculogenesis (Carmeliet et. al, 1999), although their contribution to each respective 
process is simply one of many other signaling factors. On the contrary, VEGF/VEGFR 
interactions, chiefly those between the respective isoforms VEGFA (otherwise known 
simply as VEGF) and VEGFR2, are the major drivers of angiogenesis (Ferrara et. al 
2003). VEGF expression is often prompted by hypoxic conditions, in which hypoxia-
induced factors (HIFs) cease to be targeted for ubiquitination; as intracellular HIF 
concentration increases, enough HIFs enter the nucleus and bind to the VEGF 
transcription factor hypoxia response element (HRE) to increase its expression (Rahimi, 
2012; Kimura et. al 2000).  
In sprouting angiogenesis, VEGF/VEGFR2 binding first rearranges adhesive 
connections between endothelial cells and then prompts endothelial cells to proliferate in 
order to branch off the existing vessel (Gerber et al, 1998; Stapor et al, 2014). The 
foremost cell, aptly referred to as a “tip” cell (Jakobsson et. al 2010), leads the 
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progression of branching “stalk” cells into the avascular region along a chemotactic 
VEGF gradient (Ferrara, 2010). Endothelial cells are constantly vying to be the new tip 
cell, as selection is determined largely by the endothelial cell that can sense VEGF the 
most accurately; stalk cell selection is also related to VEGF signaling, in conjunction 
with Notch signaling (Jakobsson et. al 2010). Tip and stalk cells have also been shown to 
display different morphologies that correlate with their angiogenic roles (Phng and 
Gerhardt, 2009). Tip cells, specialized for leading the migration of stalk cells down the 
VEGF gradient, possess numerous filopodia with which they sense the surrounding 
environment; on the other hand, stalk cells proliferate, form tighter intercellular junctions 
and deposit basement membrane proteins (Phng and Gerhardt, 2009).  
Additionally, endothelial cells use glycolysis as the preferred energetic pathway 
and regulators of glycolysis, particularly phosphofructo-2-kinase/fructo-2,6-
bisphosphate-3 (PFKFB3) direct vessel sprouting (De Bock et al. 2013). Other ligand-
receptor signaling has been demonstrated as part of angiogenesis, such as the 
angiopoietins/Ties, Notch receptor and PDGF, however much of angiogenic signalling 
remains poorly understood (Conway et. al, 2001).  
 
Pathological Angiogenesis and Anti-Angiogenic Therapies  
The process of pathological angiogenesis is much the same as physiological 
angiogenesis in that hypoxia remains the major stimulus and VEGF/VEGFR interactions 
remain the major drivers (Stapor et. al, 2014). Pathological angiogenesis, while 
prominent in cancer, is also prevalent in diseases such as macular degeneration and 
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diabetic retinopathy (Stapor et. al, 2014). Unlike in normal angiogenesis, there is no 
cessation of the signalling cascade in pathologic angiogenesis (Chung et. al, 2010). This 
is in part caused by tumor-secreted factors that continue the pro-angiogenic signal 
(Chung et al, 2010) and by an unresolved hypoxic condition due to either inadequate 
vasculature or an accelerated growth that exceeds angiogenesis (Stapor et. al, 2015).  
Vessels formed in pathological angiogenesis are not normal. Vessels often form 
irregular lumens, increase their permeability and show more variable junctional complex 
compositions (Carmeliet and Jain, 2000). In some pathological circumstances, tumor 
cells themselves acquire vasculogenic properties and mimic healthy endothelial cells, 
referred to as “vascular mimicry” (Maniotis et. al, 1999; Folberg et. al 2000). Although 
still preliminary, another common theory of tumor angiogenesis posits that vasculogenic 
tissue that remains in circulation may be another source of abnormal vessels when 
recruited by tumor-secreted angiogenic factors (Stapor et. al, 2014). 
The initial approach to treating pathological angiogenesis was to block the vessels 
supplying the tumor. This approach quickly presented two issues; tumor endothelial cells 
have a different cell-surface composition than healthy endothelial cells, making it more 
difficult for drugs to bind to their respective receptors. Second, worsening the hypoxic 
condition increases the risk of metastasis (Carmeliet and Jain, 2000).  Many treatments 
now use vessel normalization, a general approach of first treating the tumor-formed blood 
vessel, then targeting the tumor with chemotherapy or other anti-cancer treatments. Anti-
VEGF therapies are also a major focus of treating tumors, as cutting off their ability to 
recruit more vessels seems to be an effective treatment (Meadows and Hurwitz, 2012).  
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Cellular Adhesion Molecules and Angiogenesis 
 Cell adhesion molecules (CAMs) are cell-surface receptor proteins that allow 
cells to adhere to each other and sense their surroundings (Cavallaro,and Christofori. 
2004), which in turn influences many critical cellular activities such as embryogenesis, 
antigen-antibody interactions and tissue repair. The CAMs afford cells adhesive qualities 
critical for proper attachment to the basement membrane and adjacent cells, and are 
grouped into one of five families: cadherins, integrins, selectins, the CD44 family and 
immunoglobulin (Ig) superfamily proteins (Okegawa et. al, 2004). The Ig superfamily 
CAMs are involved in cell adhesion and cell migration (Cavallaro,and Christofori. 2004). 
The Ig domains of these adhesion molecules function by trans-dimerization through 
homophilic or heterophilic interactions and can establish a cell’s adhesive qualities this 
way (Takai et al., 2008). 
Many CAMs also hold tumor-suppressor roles mainly because contact with the 
surrounding environment provides a consistent signal that “instructs” endothelial cells to 
remain static, a phenomenon referred to as “adhesion-mediated contact inhibition” (Moh 
and Shen, 2009; Okegawa et al, 2002). Disruption or loss of this signal, a common 
occurrence in tumor angiogenesis (Nair et al. 2005; Paschos et al. 2009), increases the 
metastatic potential of these cells not only by allowing their detachment from the 
surrounding environment, but also by promoting cell growth (Moh and Shen, 2009). 
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Identification of IGPR1, TMIGD1 and IGCR1 as novel CAMs involved in the regulation 
of cell adhesion and angiogenesis 
Recent studies in our laboratory identified multiple Ig-containing adhesion 
molecules, including immunoglobulin-containing proline-rich receptor 1 (IGPR1) and 
transmembrane and immunoglobulin domain-containing 1 (TMIGD1), that influence cell 
migration, endothelial barrier function and in the latter case, protection of cells from 
oxidative cell injury (Arafa, et. al., 2015; Rahimi et. al., 2012, Wang et. al 2016).   
 The third of these CAMs is called immunoglobulin-containing cysteine-rich 
receptor 1 (IGCR1) and is a 45 kDa transmembrane protein that shares much of its amino 
acid sequence with IGPR1 and TMIGD1. IGCR1 also influences cellular adhesion, cell 
spreading and migration.  
The primary goals of this study were to determine the expression and function of 
IGCR1 in endothelial cells. Specifically, the objectives of this study were to (a) 
determine the expression of IGCR1 in blood vessels and endothelial cells in culture (b) 
determine the biological importance of IGCR1 in angiogenesis, and (c) examine the 
signaling mechanisms of  IGCR1 in angiogenesis.       	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MATERIALS AND METHODS 
 
 
Antibodies and Reagents 
The antibody rabbit polyclonal anti-IGCR1 was developed that specifically 
recognizes the extracellular domain of IGCR1 in house. Rabbit polyclonal anti-PLCγ1 
and mouse polyclonal anti-c-myc as well as horseradish peroxidase (HRP)-conjugated 
goat anti-rabbit antibody (cat # sc-2004) and horseradish peroxidase (HRP)-conjugated 
goat anti-mouse antibody were purchased from Santa Cruz Biotechnology Inc. (Santa 
Cruz, CA). Rabbit polyclonal anti-phospho-p44/42 MAPK, rabbit polyclonal anti-p44/42 
MAPK and rabbit polyclonal-phospho-Akt and rabbit polyclonal anti-Akt were 
purchased from Cell Signaling Technology (Beverly, MA).  
 
Immunohistochemistry 
  Human tissue samples were provided by Boston University Department of 
Pathology (Boston, MA). After formalin fixation and paraffin embedding (FFPE), 5µm 
sections were cut and mounted on slides. Sections were de-paraffinized, hydrated, and 
rinsed in distilled water (dH2O), then subject to heat-induced V antigen retrieval with 1X 
citrate buffer [10 mM citric acid and 0.05% Tween-20, pH 6.0] for 20 minutes at 98ºC. 
Slides were then rinsed in dH2O and blocked with 200-500µL 1X blocking buffer [made 
from 10X Power Block Universal Blocking Reagent] (cat # HK085-5K; BioGenex, 
Fremont, CA) for 30 minutes at room temperature in a humidified chamber. After 
removal of this 1X blocking buffer, rabbit anti-IGCR1 antibody was diluted in 1X 
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blocking buffer and added to each section for 60 minutes. The primary antibody solution 
was removed from the section and washed for five minutes three times in Western 
Rinse buffer.  
One-Step Polymer-HRP (cat # HK595-50K; BioGenex) was then added to the 
sections and incubated for 30 minutes in a humidified chamber. Next, Polymer-HRP was 
removed from the sections and washed three times in Western Rinse. 3% hydrogen 
peroxide solution was added to each sample for 15 minutes after the third wash and then 
washed three more times in Western Rinse. Western Rinse was removed from each 
sample and then 100L DAB solution consisting of 20µL DAB Chromogen (cat # HK124-
05K; BioGenex) and 1 mL Stable DAB Buffer (cat # HK520-50K; BioGenex) was added 
to each tissue sample. After a three minute incubation, samples were immediately 
immersed in dH2O and counterstained in Mayer’s hematoxylin for 10 seconds. After the 
sections were dehydrated and mounted, microscopy images were taken at 40X. 
 
Cell Culture 
Human embryonic kidney-293 (HEK-293) cells and porcine aortic endothelial 
(PAE) cells were grown in Dulbecco’s modified essential medium (DMEM) that 
contained 10 % fetal bovine serum (FBS). GPG cells were grown in 293 GPG growth 
medium, 10% FBS/DMEM that also contained 1 µg/mL tetracycline, 2 µg/mL Puromycin, 
0.3 mg/mL G418, 10 mM HEPES, and 6 mL L-glutamine. All cells were placed in a 5% 
CO2 humidified chamber and incubated at 37°C. HEK and PAE cells expressing empty 
vector (pQ) or IGCR1 were generated using a pQ vector as described (Rahimi et al., 
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2000). 
 
Western Blot Analysis 
Cells were washed three times with H/S buffer [25mM Hepes [pH 7.4]/150mM 
NaCl] and then lysed in EB lysis buffer [10mM Tris-HCl/10% Glycerol/ 5 mM EDTA 
(pH 7.4)/ 50 mM NaCl/50 mM NaF/1% Triton X-100/ 1 mM phenylmethylsulfonyl 
fluoride/2 mM sodium orthovanadate/aprotinin (20 mg/ml)]. The cell lysates were 
collected and then mixed with 5X Sample Buffer [bromophenol blue (0.25%)/ 
dithiothreitol (DTT) (0.5M)/ glycerol (50%), sodium dodecyl sulfate (SDS)(10%)/Tris – 
Cl (0.25M, pH 6.8)] and heat shocked at 95°C for five minutes.  
Cell lysates were then resolved by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred on to polyvinylidene difluoride (PVDF) 
membranes and immunoblotted with antibodies targeting the proteins of interest. For 
some experiments, membranes were stripped using stripping buffer [β-Mercaptoethanol 
/1M Tris-HCl pH 6.8/20%SDS (690µl/100 ml)] and then re-probed with another antibody.  
Antibodies were diluted in 1X TBS solution of 10% bovine serum albumin. The 
dilution for both rabbit polyclonal anti-IGCR1 antibodies was 1:2000, 1:1000 for anti-
PLCγ antibody, 1:500 for anti-c-myc antibody, 1:1000 for anti-p44/42 MAPK, anti-
phospho-p44/42 MAPK, anti-phospho-Akt, and anti-Akt antibodies. Secondary 
antibodies were used at 1:10,000 for both anti-rabbit-IgG HRP-linked antibody and 
antimouse-IgG HRP-linked antibody. 
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Cell Spreading Assay 
 An equal number of HEK and IGCR1/HEK cells were seeded into a 6-well tissue 
culture plate containing collagen matrix and incubated for 20 minutes, then fixed using 
Diff-Quik ® Stain Set purchased from Dade Behring [Fixer: 1.8 mg/L Triarylmethane 
dye in methyl alcohol; Stain 1: 1g/L Xanthene dye, buffer and sodium azide (0.01%); 
Stain 2: 1.25 g/L Thiazine Dye mixture (0.625 g/L Azure A and 0.625 g/L Methylene 
Blue) and buffer]. Cells were imaged at 10x magnification. This experiment was repeated 
twice. 
 
Disulfide Dimerization Assay 
 One “group” of HEK and IGCR1/HEK cells were lysed as described above. A 
second group was also lysed but β-Mercaptoethanol was absent from the 5x Sample 
Buffer. Samples were resolved by SDS-PAGE, with two lanes of β-Mercaptoethanol-free 
2x Sample Buffer separating the samples of each group, and developed according to the 
Western blot protocol above. Probing for IGCR1 used rabbit polyclonal anti-IGCR1 
antibody 606. This experiment was repeated twice. 
 
Trypsinization Assay 
 5 mL of trypsin/EDTA tissue culture medium was added to one plate of EV/PAE 
cells and the plate was imaged under 10x magnification every minute for 6 minutes total, 
then repeated with one plate of IGCR1/PAE cells. This experiment was repeated twice. 
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Cell Proliferation (MTT) Assay 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay kit (CellTiter 
96 Non-Radioactive Cell Proliferation Assay) purchased from Promega (Madison, WI) 
was used to measure endothelial cell survival. PAE cells (2x103 cells/mL) expressing 
empty vector and IGCR1 were seeded into four 24-well tissue culture plates in 10% 
FBS/DMEM media. After 3 hours, the 10% FBS/DMEM media was replaced with 0% 
FBS/DMEM media.  
At day 0 (24 hours from seeding) an MTT yellow tetrazole dye was added to 6 
wells at a concentration of 10µL/400µL of media and incubated for two hours at 37°C. 
Stop solution (Promega) was added to solubilize the insoluble 12-purple formazan that 
was produced as a result of metabolism during incubation, and the cells were incubated 
for one hour at 37°C. After incubation, 200µL of solubilized solution from the wells was 
transferred to a 96-well plate with four wells per group and underwent 
spectrophotometric analysis at 570 nm. This spectroscopy test was repeated for the next 6 
wells on days 2, 4 and 6 and repeated in full twice.  
 
Cell Migration (Wounding) Assay 
PAE cells (2x103) expressing empty vector and IGCR1 were plated in DMEM 
media and incubated for 24 hours until they reached confluency above 90%. The 
wounding assay was performed by using the tip of a 5mL tissue culture pipette to create 
multiple “wounds” or scratches across the cell monolayer. Between 3-5 hours, the cell 
culture plates were viewed under microscope. Images were captured and documented. 
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This experiment was repeated twice. 
 
Endothelial Cell Capillary Tube Formation Assay 
PAE cells overexpressing IGCR1 and PAE cells expressing empty vector were 
seeded on matrigel with endothelial cell growth medium (Clonetics, San Diego, CA). 
After 24 hours, capillary tube formation was viewed under microscope and photographed 
as described (Meyer et al., 2008). Quantification of capillary tube formation was 
established by using ImageJ (National Institutes of Health, Bethesda, MD).  
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RESULTS 
 
 Characterization of anti-IGCR1 antibodies 
To study the expression and function of IGCR1, we developed two rabbit polyclonal 
antibodies against the extracellular domain of IGCR1. The two IGCR1 antibodies, clones 
605 and 606, were compared for specificity in Western blot analysis (Figure 1a). Since 
expression of IGCR1 in human cell lines is not known, we also generated a HEK-293 cell 
line over-expressing IGCR1 (herein called IGCR-1/HEK-293).  Accordingly, we used 
cell lysates derived from HEK-293 cells expressing an empty vector (EV/HEK-293) or 
IGCR1and assessed the specificity of IGCR1 antibodies. Clone 606 anti-IGCR1 antibody 
(1:2,000) detected a specific protein band with an approximate molecular weight of 
45kDa, which also corresponds to the predicted molecular weight of IGCR1 (Figure 2).  
The anti-IGCR1 antibody (clone 606) was further tested in western blotting in various 
dilutions ranging from 1:2000, 1:8000, 1:10,000 and 1:20,000.  Clone 606 specifically 
recognized  IGCR1 up to 1:20,000 dilutions (Figure 1b).  
After validating the specificity of clone 606 in western blot analysis, we decided 
to test whether clone 606 also reacts with IGCR1 in immunohistochemistry staining.  The 
result showed that clone 606 specifically stained endothelial cells of blood vessels in PFA 
fixed human tissue. (Figure 1c).  This observation promoted us to investigate expression 
of IGCR1 in endothelial cells.  Our analysis showed that IGCR1 is endogenously 
expressed in human transformed umbilical vein endothelial cells (HUVEC-TERT) and 
porcine aortic endothelial (PAE) cells (Figure 3). 
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Figure 1. Antibody 606 is specific to IGCR1. (A) Antibodies 605 and 606 were 
compared for specificity. 605 has multiple nonspecific bands while 606 has fewer and is 
more specific. (B) Antibody 606 dilutions were compared and was found to be specific to 
IGCR1 up to 1:20,000 dilution. (C) Antibody 606 was used for immunohistochemistry 
staining of various tissues to identify areas of endogenously increased IGCR1. This large 
artery in the breast tissue was identified as one such area. 
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Figure 2. Ig-containing cysteine rich receptor 1 (IGCR1) amino acid sequence. The 
predicted molecular weight of IGCR1 is 45.1 kDa. IGCR1 contains two Ig domains, one 
transmembrane region and its intracellular region is rich in cysteine residues.  
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Figure 3. IGCR1 is expressed endogenously in endothelial cells. Protein loading 
control and expression of IGCR1 in transformed human umbilical vein endothelial 
cells, with transduced PAE cells as positive and negative controls.  
 
IGCR1 regulates cell spreading and cell adhesion 
 To investigate the possible functions of IGCR1, we ectopically expressed IGCR1 
in HEK-293 cells via a retroviral expression system (Figure 4a). Considering the role of 
other IGCR1-related cell adhesion molecules in cell spreading and adhesion (Rahimi, et 
al. 2012, Arafa, et al., 2015, Wang et al., 2016), we specifically examined whether 
expression of IGCR1 in HEK-293 cells could affect spreading of HEK-293 cells.  Our 
initial observation showed that expression of IGCR1 in HEK-293 cells significantly 
altered the morphology of these cells (Figure 4b, Figure 5).  Additionally, HEK-293 
cells expressing IGCR1 were generally resistant to trypsinization, as assessed by their 
apparent change in their morphology and detachment from the cell culture plates (Figure 
4b).   
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Figure 4. IGCR1 changes the morphology of HEK cells. (A) Western blot analysis of 
HEK and IGCR1/HEK. (B) Images of HEK and IGCR1/HEK cells under 10x 
magnification. 
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Expression of IGCR1 in HEK-293 cells regulates cell spreading  
Having observed the specific effect of IGCR1 in HEK-293 cells’ morphology and 
adhesion, we decided to specifically examine the effect of expression of IGCR1 in the 
spreading of HEK-293 cells. To this end, an equal number of HEK-293 cells and  
IGCR1/HEK293 cells were added to collagen-coated plates. After twenty minutes, cells 
were fixed, stained and imaged under 10x magnification (Figure 5). IGCR1/HEK-293 
cells were found to have spread across the plate more than the HEK-293 control group. 
Morphologically, the IGCR1/HEK-293 cells also appeared to have longer and increased 
numbers of filipodia and lamellipodia, and their cell nuclei also appeared more 
euchromatic than the control (Figure 5).
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Figure 5. IGCR1 promotes cell spreading. An equal number of HEK cells and HEK 
cells expressing IGCR1 were added to collagen-coated plates and allowed to spread for 
20 minutes. Both plates were then fixed, stained and imaged under 10x magnification. 
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 Potential dimerization of IGCR1 
Considering that usually immunoglobulin domain-containing cell adhesion 
molecules undergo disulfide bond formation, we decided to examine possible 
dimerization of ICGR1 expressed in HEK-293 cells (Barclay, 2003). To this end, HEK-
293 control cells and IGCR1/HEK-293 cells were lysed and denatured in sample buffer 
with and without β-mercaptoethanol and resolved in SDS-PAGE, followed by western 
blot analysis (anti-IGCR1 antibody 606, 1:2000) (Figure 6). If the Ig-containing domains 
did dimerize, the expected signal would move from about 45 kDa to about 90 kDa. 
However, the IGCR1 apparent molecular weight did not change in the β-mercaptoethanol, 
suggesting that IGCR1 does not undergo disulfide bond-mediated dimerization.   
 
Figure 6. IGCR1 does not form disulfide bond mediated dimerization in HEK-
293 cells. HEK-293 cells and HEK-293 cells expressing IGCR1 were lysed and 
denatured in sample buffer with and without β-mercaptoethanol and then probed for 
IGCR1. 
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 Biological function of IGCR1 in PAE cells 
 To examine the effects of IGCR1 on the function of endothelial cells, we studied 
porcine aortic endothelial cells (PAE cells) ectopically expressing IGCR1. The 
expression of IGCR1 is shown (Figure 8a). Initially, we examined PAE cells expressing 
IGCR1 for its effect on cell adhesion. In particular, if the expression of IGCR1 in PAE 
cells was to increase the adhesive properties of these cells, it is expected that these cells 
would require a longer time to undergo detachment form the cell culture plates than their 
parental control cells.  Our observation showed that detachment of PAE cells expressing 
IGCR1 in response to trypsin was much slower than the parental PAE cells (Figure 7)   
The adhesive strength of cells is generally proportional to their trypsinization time 
in culture (Rahimi et al, 2012). PAE-EV cells require about 2-3 minutes of trypsinization 
in trypsin/EDTA medium. On the contrary, PAE cells overexpressing IGCR1 were 
qualitatively observed to need more time to trypsinize, about 3-4 minutes. Furthermore, 
even when trypsinized, PAE-IGCR1 cells adhered more strongly to the plate than the 
corresponding control group and only disengaged when repeatedly agitated with a 
pipette. To quantify this observation, a single plate of PAE cells were trypsinized, 
observed and imaged in 10x magnification until all had disengaged from neighboring 
cells and the plate, a period of about 6 minutes (Figure 7a). Images were taken every 
minute to track changes in morphology and adhesion. A plate of PAE-IGCR1 cells was 
subsequently trypsinized, observed and imaged in the same manner (Figure 7b).  
 Most cells in the PAE control group, as expected, had disengaged after about 2 
minutes in the trypsin/EDTA medium and fully dislodged from the cell plate within 3 
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minutes. In contrast, PAE-IGCR1 cells were still predominantly attached to the plate after 
2 minutes and showed little morphological change. At 4 minutes, the overexpressing cells 
did appear more rounded but were still associating closely with neighboring cells. After 5 
minutes, eventually all cells were totally disengaged. 
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Figure 7. IGCR1 increases cell adhesion. Trypsin was added to (A) PAE-EV and 
(B) PAE-IGCR1 cell cultures, which were imaged every minute to track 
morphological changes. 
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IGCR1 regulates the angiogenic properties of PAE cells 
Endothelial cells remain in a quiescent state for most of their lives, emerging from 
this state when they form new blood vessels (Stapor et al 2014).  Therefore, it was 
postulated that as a CAM highly expressed by endothelial cells, IGCR1 could play a role 
in angiogenesis. Angiogenesis, while complex, consists of three main cellular processes: 
cell proliferation, cell migration and capillary tube formation (Stapor et al 2014). To 
study the effects of IGCR1 on angiogenesis, three assays for each of these processes were 
conducted on PAE cells transduced with empty vector and IGCR1. The results, stated in 
detail below and summarized in Table 1, likely represent IGCR1’s total effect on 
angiogenesis. 
 
Angiogenic process Method used Likely effect of IGCR1 
Cell Proliferation and Cell Survival MTT assay Inhibition 
Cell Migration Wounding assay Promotion 
Capillary Tube Formation Matrigel assay Inhibition 
 
Table 1. A summary of the angiogenic processes assayed and their findings. 
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IGCR1 inhibits proliferation of PAE cells 
 To determine IGCR1’s effect on cell proliferation, PAE-EV and PAE-IGCR1 
cells were subjected to an MTT assay. Cells were plated in Fetal Bovine Serum (FBS) 
conditions of 10% and 0% and were assayed every other day for six days (Figure 8).  
Proliferation was measured to be faster in the cells in the PAE-EV cells in both 
conditions. This observation may indicate that IGCR1 has a negative effect on cell 
proliferation. Also, the proliferation was more pronounced in the 10% FBS conditions for 
both cell lines, leading to the possibility that a ligand for IGCR1 is found in Fetal Bovine 
Serum.  
 
Figure 8. IGCR1 inhibits cell proliferation. (A) Expression of IGCR1 in PAE cells 
expressing empty vector vs. PAE cells overexpressing IGCR1 and protein loading 
control. (B) Cell proliferation as measured by MTT assay. Error bars indicate range 
of percent error. 
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IGCR-1 stimulates migration of PAE cells 
To study IGCR1’s effect on endothelial cell migration, PAE-EV and PAE-IGCR1 
cells were subjected to a wound-healing assay. Cell plates were gently scratched to clear 
cells in a single line. Cells then migrated across this line and plates were monitored over 
a period of 4 hours for progression of the “wound healing” and imaged in 10x 
magnification between 3 to 4.5 hours (Figure 9). At 3.5 hours, PAE-IGCR1 cells had 
begun to migrate across the wound and at 4 hours, had almost totally “healed,” as 
opposed to the PAE control group, which only started to migrate around 4.25 hours. 
IGCR1 thus appeared to increase the migratory properties of these cells. 
 
Figure 9. IGCR1 promotes cell migration. PAE cells expressing empty vector and 
IGCR1 were subjected to wounding assay and imaged over a period of 5 hours. 
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 IGCR1 inhibits capliary tube formation of PAE cells  
 To study IGCR1’s effect on endothelial cell migration, PAE-EV and PAE-IGCR1 
cells were subjected to a capillary tube formation assay. An equal number of cells of each 
line were plated on a Matrigel matrix and incubated for 12 hours and imaged in 10x 
magnification. Tube formation in the PAE-IGCR1 group was almost nonexistent after 12 
hours while the PAE-EV cells were able to form capillary tubes (Figure 10). The amount 
of capillary tubes formed was quantified using Image J, which demonstrated that 
endothelial cells overexpressing IGCR1 are barely able to form capillary tubes, and in the 
event that the tubes do form, they form more slowly and less frequently. 
Figure 10 IGCR-1 inhibits capillary tube formation of PAE cells. (A) PAE cells 
expressing empty vector or IGCR1 were subjected to Matrigel assay and pictures were 
taken after 24 hours. (B) Quantitative analysis of the average length of the branches 
between PAE-EV and PAE-IGCR1.    
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IGCR1 regulates phosphorylation of PI3-kinase and MAPK pathways 
After establishing that IGCR1 does seem to play a role in angiogenesis, a 
phosphorylation study was conducted using PAE cells expressing empty vector or 
IGCR1. For each group, cells were incubated for 6 hours in either 0% or 10% FBS, then 
lysed and run in a western blot. Probing for phosphorylation of major enzymes in the 
MAPK/ERK pathway and the PI3K-Akt pathway revealed that PAE-IGCR1 cells 
possessed more phosphorylated-ERK (p-ERK) than the empty vectors in both 0% and 
10% FBS (Figure 11a). In addition, Akt was phosphorylated to a minor extent in both 
empty vector and IGCR1 cells growing in serum free conditions, PAE-EV cells growing 
in 10% FBS conditions particularly phosphorylated Akt, while there was a distinct lack of 
p-Akt in PAE-IGCR1 cells growing in 10% FBS conditions (Figure 11b). 
 
Figure 11. Akt and ERK phosphorylation in PAE-EV and PAE-IGCR1 cells. All 
antibodies were used in 1:1000 dilutions. (A) PAE cells expressing IGCR1 
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DISCUSSION 
 In this study, we demonstrate that IGCR1 is a novel protein that is expressed in 
the endothelial cells of human blood vessels and that its expression in endothelial cells 
modulates angiogenesis.   
To characterize expression and possible function of IGCR1, we developed two 
rabbit polyclonal antibodies, clones 605 and 606, against the extracellular domain of 
IGCR1.  Additionally, we created HEK-293 cells consistently expressing IGCR1 via a 
retroviral expression system.  
Our characterization of anti-IGCR1 antibodies demonstrated that clone 606 anti-
IGCR1 antibody specifically recognizes IGCR1 in western blot analysis.     
Moreover, immunohistochemistry staining using clone 606 antibody revealed that 
the vasculature, particularly the tunica intima, strongly expressed IGCR1. Taken together 
with the qPCR data of human tissues, which showed high levels of IGCR1 mRNA in 
human arteries (Kobra Rezazadeh, unpublished data) and data presented in this present 
study  IGCR1 is likely highly expressed by endothelial cells and may play a role in 
endothelial cell functions such as angiogenesis . Considering that endothelial cells are 
normally quiescent yet are highly activated in pathological circumstances, it is reasonable 
to posit that IGCR1 could play a role in endothelial cell function in normal physiological 
and pathological conditions associated with blood vessels (Chung et. al, 2010). 
Before we examined the effect of IGCR1 in endothelial cells, we first investigated 
the general function of IGCR1 in human cells. To this end, IGCR1/HEK-293 and its 
parental control HEK-293 were used. Cell spreading is an inherent quality of all cells, 
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and the data presented in this study demonstrates that overexpression of IGCR1 in HEK 
cells increased their spreading. We noticed that after 20 minutes on collagen-coated 
plates HEK cells over-expressing IGCR1 not only spread more than the control cells, but 
also gained more filopodia and lamellipodia and associated with their neighboring cells 
more closely. Of note, the nuclei of these overexpressing cells appeared more 
euchromatic than the control, which is an indication of increased cell activity, consistent 
with the overall increase in motility.  
 Other members of the Ig superfamily cell adhesion molecules to which IGCR1 
belongs are known to homophilically dimerize via disulfide bridges (Walter Wang, et al. 
2016). Unexpectedly, we observed that IGCR1 does not form disulfide bond-mediated 
dimerization. Further pursuit of IGCR1 dimerization is a worthwhile endeavor and should 
be addressed in future research. 
Next, we explored the role of IGCR1 in endothelial cell function. For this 
purpose, PAE cells were transduced using a retroviral method to express empty vector 
(EV) or IGCR1. Cell adhesion is an inherent quality of all cells, and is a critical 
characteristic for proper vascular function (Rahimi, et al. 2012, Arafa, et al., 2015, Wang 
et al., 2016). While IGCR1/HEK-293 cells were observed to adhere more strongly to 
each other and the cell culture plate, cell adhesion was specifically studied using PAE 
cells in order to determine IGCR1’s possible effect specifically on endothelial cell 
adhesion. Cell adhesion is directly related to trypsinization time (Rahimi et al., 2012). 
When EV/PAE or IGCR1/PAE cells were trypsinized and imaged, the latter group 
adhered more strongly to the plate and did not begin to exhibit the token morphological 
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change desired during cell passaging until after 3 minutes had passed, while cells in the 
former had already retracted their connections before 3 minutes. Not as obvious from the 
static figures provided, the rate at which the two groups retracted their connections 
differed greatly. On the whole, the IGCR1/PAE cells were slower to disengage from their 
neighbors, demonstrating that IGCR1 appears to increase the adhesive properties of 
endothelial cells.  
It is widely known that tumorigenic endothelial cells are able to delaminate and 
move through the vasculature in part due to not being as tightly adhered to each other or 
the basement membrane (Stapor et. al, 2014). As a corollary of this, many CAMs, by 
virtue of their function, hold tumor-suppressor roles. IGCR1’s effect of increasing the 
adhesive properties of endothelial cells may suggest that it also assumes such a role.  
To study the effects of IGCR1 on the overall process of angiogenesis, we 
separated aspects of angiogenesis into cell proliferation, migration and capillary tube 
formation and ran respective assays using IGCR1/PAE and EV/PAE cells. The results of 
a cell proliferation assay by MTT showed that IGCR1 not only has an inhibitory effect on 
cell proliferation in both starved and normal conditions, but also that the fetal bovine 
serum (FBS) used in cell culture media may contain a ligand for IGCR1.  A wounding 
assay demonstrated that cell migration was also increased in IGCR1/PAE cells. The third 
aspect of angiogenesis tested was capillary tube formation and the findings of this study 
show IGCR1 has a significant inhibitory effect on this process. 
Taken together with the findings of IGCR1’s expression in the endothelium of 
mature vessels and that IGCR1 increases endothelial cell adhesion, IGCR1 most likely 
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functions in non-angiogenic vessels to maintain the endothelial cell barrier, and in 
angiogenesis as a mediator of cell migration.  
To initially characterize IGCR1’s intracellular signaling in endothelial cells, we 
sought to distinguish which key molecular pathways, Akt and ERK/MAPK, were 
activated by starved and normal conditions. Our data showed that ERK is highly 
phosphorylated in IGCR1/PAE cells, particularly in starved conditions, suggesting that 
perhaps IGCR1 exerts its effects on cell migration and cell spreading by altering ERK 
activation. Furthermore, our data showed that Akt phosphorylation, a key protein 
involved in cell proliferation and cell survival, is inhibited by IGCR1, suggesting that 
perhaps IGCR1 reduces the proliferation rate of endothelial cells by inhibiting AKT 
phosphorylation. 
Further studies should further validate the anti-IGCR1 antibody using a blocking 
peptide, but also continue characterizing IGCR1’s molecular signaling in response to 
different stimuli; the only stimulus tested here was the absence of FBS in the cell media. 
As results indicated differing responses in these two conditions, it is likely that FBS 
contains a ligand to IGCR1, and future research should identify this ligand or ligands. 
IGCR1’s effects on cellular processes, particularly angiogenesis, would be further 
illuminated by knockdown studies. Lastly, and as mentioned above, further study into 
IGCR1’s ability to increase cell adhesion has the potential to benefit many anti-
angiogenic and anti-metastasis therapeutic approaches.  
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